Human host defense peptide LL-37 stimulates virulence factor production and adaptive resistance in Pseudomonas aeruginosa

PLoS One. 2013 Dec 13;8(12):e82240. doi: 10.1371/journal.pone.0082240. eCollection 2013.

Abstract

A multitude of different virulence factors as well as the ability to rapidly adapt to adverse environmental conditions are important features for the high pathogenicity of Pseudomonas aeruginosa. Both virulence and adaptive resistance are tightly controlled by a complex regulatory network and respond to external stimuli, such as host signals or antibiotic stress, in a highly specific manner. Here, we demonstrate that physiological concentrations of the human host defense peptide LL-37 promote virulence factor production as well as an adaptive resistance against fluoroquinolone and aminoglycoside antibiotics in P. aeruginosa PAO1. Microarray analyses of P. aeruginosa cells exposed to LL-37 revealed an upregulation of gene clusters involved in the production of quorum sensing molecules and secreted virulence factors (PQS, phenazine, hydrogen cyanide (HCN), elastase and rhamnolipids) and in lipopolysaccharide (LPS) modification as well as an induction of genes encoding multidrug efflux pumps MexCD-OprJ and MexGHI-OpmD. Accordingly, we detected significantly elevated levels of toxic metabolites and proteases in bacterial supernatants after LL-37 treatment. Pre-incubation of bacteria with LL-37 for 2 h led to a decreased susceptibility towards gentamicin and ciprofloxacin. Quantitative Realtime PCR results using a PAO1-pqsE mutant strain present evidence that the quinolone response protein and virulence regulator PqsE may be implicated in the regulation of the observed phenotype in response to LL-37. Further experiments with synthetic cationic antimicrobial peptides IDR-1018, 1037 and HHC-36 showed no induction of pqsE expression, suggesting a new role of PqsE as highly specific host stress sensor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoglycosides / pharmacology
  • Anti-Bacterial Agents / pharmacology
  • Antimicrobial Cationic Peptides
  • Bacterial Proteins / genetics
  • Bacterial Proteins / metabolism
  • Cathelicidins / pharmacology*
  • Drug Resistance, Bacterial* / drug effects
  • Drug Resistance, Microbial / drug effects
  • Drug Resistance, Microbial / genetics
  • Fluoroquinolones / pharmacology
  • Gene Expression Regulation, Bacterial / drug effects
  • Genes, MDR
  • Humans
  • Microbial Sensitivity Tests
  • Microbial Viability / drug effects
  • Mutation / genetics
  • Oligonucleotide Array Sequence Analysis
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / genetics
  • Pseudomonas aeruginosa / pathogenicity*
  • Virulence Factors / biosynthesis*

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Antimicrobial Cationic Peptides
  • Bacterial Proteins
  • Cathelicidins
  • Fluoroquinolones
  • Virulence Factors

Grants and funding

The authors gratefully acknowledge financial support by the BioInterfaces (BIF) Program of Karlsruhe Institute of Technology (KIT) in the Helmholtz Association, the “Concept for the Future” of KIT within the German Excellence Initiative, the Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of KIT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.